Estimating the cost‐effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England
Authors' conclusion
While isCGM is associated with increased short-term costs, compared with SMBG, its benefits in lowering HbA1c will lead to sufficient long-term health-gains and cost-savings to justify costs, so long as the effect lasts into the medium term.
Study context
- Population
- Adults with T1D and high HbA1c (58–97 mmol/mol [7.5%-11%]), England
- Comparison
- Intermittently scanned continuous glucose monitoring (isCGM) vs SMBG
- Primary endpoint
- Incremental cost-per-QALY of isCGM vs SMBG
- Follow-up
- Lifetime horizon
Methodological detailswithin-trial and lifetime model-based analysis, IQVIA CORE Diabetes Model, NHS perspective, lifetime horizon, discounted at 3.5%
- Within-trial and lifetime model-based analysis
- IQVIA CORE Diabetes Model
- NHS perspective
- Lifetime horizon, discounted at 3.5%
Primary result
As reported in the abstract
Lifetime projected incremental cost, QALY and cost-per-QALY
Incremental cost
£1954
95% CI −5108 to 8904
isCGM
Incremental QALY gain
0.436
95% CI 0.195–0.652
isCGM
- Incremental cost-per-QALY
- £4477
Further findings
| Outcome | Estimate |
|---|---|
| Within-trial QALY and cost · 24 weeksisCGM vs SMBG · non-significant | adjusted incremental QALY gain 0.006 (95% CI −0.007 to 0.019) |
| Within-trial QALY and cost · 24 weeksisCGM vs SMBG | adjusted cost increase per participant £548 (95% CI 381–714) |
Subgroups · lifetime
- In all subgroups, isCGM incremental cost-per-QALY better than £20,000 vs SMBG
- Baseline HbA1c >75 mmol/mol (9.0%): isCGM cost-saving
Sensitivity analysis
- isCGM remains cost-effective if its effectiveness lasts for at least 7 years
Original publication
Estimating the cost‐effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabet Med. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →